vinblastine..... 4 mg/sqm IV day 1.
bleomycin....... 15 U/day IM on days 1 to 7.
cisplatin....... 60 mg/sqm IV day 8.
FREQUENCY....... Repeat cycle every 3 weeks for 3 cycles.
Brown AW Jr. Blom J. Butler WM. Garcia-Guerrero G.
Richardson MF. Henderson RL. Combination chemotherapy with
vinblastine, bleomycin, and cis-diamminedichloroplatinum (II)
in squamous cell carcinoma of the head and neck. Cancer.
45(11):2830-5, 1980 Jun 1.
Forty-five patients with advanced squamous cell carcinoma of
the head and neck, 23 of whom had received no prior therapy,
were given the combination of vinblastine, 4 mg/m2
intravenously (IV) on Day 1; bleomycin, 15 mg/day
intramuscularly on Days 1-7; and cis-diamminedichloroplatinum
(II), 60 mg/m2 with mannitol diuresis on Day 8. The regimen
was repeated at three-week intervals, for a maximum of three
cycles. Among the 23 patients without prior surgery or
radiation, there were 5 complete responses and 12 partial
responses, a 74% response rate; whereas, among the 22 with
prior therapy, there were 2 complete responses and 8 partial
responses, a response rate of 45%. Nineteen of 23 previously
untreated patients were subsequently given radiation, 1 had
surgery, and 1 had surgery plus radiation. Twelve of these 19
patients are currently free of disease, with a median duration
of ten months from initial response. Four of the 22 previously
treated patients received radiation and 2, surgery; 4 of these
6 patients are without evidence of disease. Renal dysfunction
with elevation of serum creatinine occurred in 5 patients, a
leukocyte count of less than 3,000/mm3 in 3, a platelet count
of less than 100,000/mm3 in 2, skin changes in 11, hearing
loss in 1, and both peripheral neuropathy and pulmonary
changes in 1 patient. This combination of agents has
substantial activity in untreated patients and may be useful
as initial therapy in advanced head and neck malignancies by
diminishing the incidence of local recurrence and distant